Latin America Pharmaceutical Blister Packaging Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook 2026-2030

Blister packaging serves as the primary unit-dose packaging solution for pharmaceutical tablets and capsules in Latin America, offering superior product protection, extended shelf life, and enhanced patient compliance compared to bulk bottle packaging. The market encompasses a broad range of material formats including polyvinyl chloride (PVC), polypropylene (PP), polyethylene terephthalate (PET), and aluminum cold-form foils, each selected based on product sensitivity, moisture barrier requirements, and cost considerations. Domestic pharmaceutical manufacturers across the region rely heavily on blister packaging to meet both internal regulatory standards and export market requirements.

• •Market valued at $1.28 billion in 2025 with a 7.4% compound annual growth rate driven by pharmaceutical sector expansion
• •Thermoformed PVC and cold-form aluminum blister formats dominate the product mix, with PVC remaining the most widely used material due to cost-effectiveness
• •Brazil, Mexico, and Argentina account for the majority of regional demand, with smaller but fast-growing markets in Colombia, Chile, and Peru

The expansion of the generic pharmaceutical industry across Latin America serves as the single largest growth catalyst, as generic drug manufacturers produce massive volumes of solid oral dosage forms that require high-speed blister packaging solutions. Rising healthcare access driven by government-subsidized programs and expanding private insurance coverage has increased prescription volumes, directly translating to higher blister packaging consumption. Additionally, multinational pharmaceutical companies establishing manufacturing and packaging operations in free-trade zones across the region require internationally compliant blister packaging that meets stringent quality and regulatory standards.

• •Growing elderly population across the region increases demand for chronic disease medications packaged in unit-dose blister formats
• •Stringent regulatory requirements for anti-counterfeiting, child-resistant packaging, and tamper evidence are pushing conversions from simple PVC to higher-value barrier blister formats
• •Export-oriented pharmaceutical production, particularly to the United States and European Union, drives demand for blister packaging meeting international pharmacopoeia standards

By material, the market is segmented into PVC-based blister packaging, which holds the largest share due to its clarity and cost advantage; cold-form aluminum blister packaging, which offers superior moisture and oxygen barrier properties for sensitive products; and emerging materials such as PP and PET for specialty applications. Regionally, Brazil leads with the largest pharmaceutical manufacturing base and domestic blister packaging production capacity, followed by Mexico, which benefits from proximity to the U.S. market and significant foreign direct investment in pharmaceutical manufacturing. Central American and Caribbean markets represent smaller but strategically important segments as regional pharmaceutical distribution hubs.

• •PVC blister packaging commands the largest volume share, while cold-form aluminum blister packaging is the fastest-growing segment due to demand for moisture-sensitive products
• •Brazil represents the largest national market, followed by Mexico and Argentina; the Andean region including Colombia and Chile shows the highest percentage growth rates
• •Horizontal sealing machines and blister packaging lines represent the dominant packaging technology, with a gradual shift toward high-speed automated systems

What are the recent trends and outlook?

Sustainability is emerging as a defining trend, with growing industry interest in polyvinylidene chloride (PVDC)-free and PVC-reduced blister packaging formulations to meet environmental regulations and corporate sustainability targets in key markets. Digital serialization and track-and-trace capabilities integrated directly into blister lidding films are gaining traction as governments implement stricter anti-counterfeiting mandates. Over the 2025 to 2030 forecast horizon, the market is expected to sustain its 7.4 percent CAGR trajectory as regional pharmaceutical capacity expands, driven by continued investment in domestic drug manufacturing, biosimilar production growth, and the progressive shift toward unit-dose packaging formats across both generic and branded pharmaceutical segments.

• •Growing adoption of child-resistant and senior-friendly blister packaging designs in response to evolving pharmacopeia requirements across Brazil, Mexico, and Argentina
• •Investment in local blister packaging manufacturing capacity is increasing, with several multinational converters expanding facilities to serve growing domestic and export demand
• •Smart packaging integration, including QR codes and digital authentication features on blister lidding materials, represents an emerging opportunity for packaging converters and pharmaceutical manufacturers alike